SLC2A1 and non-small cell lung carcinoma: It was reported that treating breast cancer cells and non-small cell lung cancer (NSCLC) cells with antibodies targeting Glut-1 reduced proliferation in human cancer cell lines in vitro and enhanced apoptosis induced by chemotherapeutic agents [56].